Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches

The recent success of Poly (ADP-ribose) polymerase (PARP) inhibitors has led to the approval of four different PARP inhibitors for the treatment of BRCA1/2-mutant breast and ovarian cancers. About 40–50% of BRCA1/2-mutated patients do not respond to PARP inhibitors due to a preexisting innate or int...

Full description

Bibliographic Details
Main Authors: Sayra Dilmac, Bulent Ozpolat
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/15/14/3642